摘要
Abstract
Objective:To explore the effect of Polyethylene Glycol Recombinant Human Growth Hormone on children with idiopathic short stature(ISS).Method:A total of 120 ISS children admitted to the Pediatrics Department of Jingzhou Third People's Hospital from January 2019 to June 2024 were selected and divided into control group(n=60,treated with Human Growth Hormone Injection)and observation group(n=60,treated with Polyethylene Glycol Recombinant Human Growth Hormone),and both groups continued to be treated for 6 months.The levels of insulin-like growth factor-1(IGF-1),height and weight,thyroid function,bone metabolism indexes[cross-linked carboxy-terminal peptide of type Ⅰ collagen(ⅠCTP),amino-terminal propeptide of type Ⅰ procollagen(P1NP),osteocalcin(OC)]and adverse reactions were compared between the two groups.Result:After treatment,the height,weight and IGF-1 of the observation group were(135.91±10.51)cm,(35.68±2.12)kg and(333.94±14.09)ng/mL,which were higher than those of the control group(P<0.05).After treatment,there were no significant differences in serum FT3,FT4 and thyroid stimulating hormone(TSH)levels between the two groups(P>0.05).After treatment,theⅠCTP,P1NP and OC in the two groups were higher than those before treatment,and those of the observation group were higher than those of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Polyethylene Glycol Recombinant Human Growth Hormone can effectively regulate the level of IGF-1 in ISS children,improve their bone metabolism indexes,and do not affect the thyroid function of children,and do not increase adverse reactions.关键词
聚乙二醇重组人生长激素/特发性矮小症/胰岛素样生长因子-1/甲状腺功能Key words
Polyethylene Glycol Recombinant Human Growth Hormone/Idiopathic short stature/Insulin-like growth factor-1/Thyroid function
